Filing Flows › IDEX (IEX) › Q3 2026
IDEX (IEX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 28, 2026
IDEX (IEX) reported revenue of $952M for the third quarter 2026 (Q3 2026), +8% from a year earlier and +3% from the quarter before. Operating margin was 21.9%, net earnings $144M (15.1% of revenue).
IDEX, Q3 2026: revenue $952M (+8% year over year), operating margin 21.9%, net earnings $144M, operating cash flow $240M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $952M | +3% | +8% |
| Gross profit | $430M | +0.6% | +10% |
| Operating profit | $208M | +4% | +12% |
| Net earnings | $144M | +0.4% | +13% |
| Operating cash flow | $240M | +20% | +18% |
| Free cash flow | $214M | — | +14% |
What changed
Revenue was $951.7M in Q3 2026, up 8% year over year and up 3% from the previous quarter. Health & Science Technologies was the largest line at 45% of revenue. Health & Science Technologies added $52.4M year over year (up 14%), 72% of the total change.
Gross margin was 45.1%, up 0.7 points from Q3 2025. Operating profit was $208.0M, a 21.9% margin (up 0.7 points year over year). Of the extra revenue versus Q3 2025, 30% reached operating profit, above the 21% margin then. Operating expenses grew 8% against revenue growth of 8%. Net earnings were $144.1M, up 13% year over year. The effective tax rate was 25.3%.
Operating cash flow was $239.5M (up 18% year over year), 166% of net earnings. Non-cash charges added back $53.4M of depreciation and amortization and $5.7M of share-based compensation. Working capital and other items added $36.4M. After capital expenditures ($25.2M), free cash flow as the company reports it was $214.3M.
Questions
What was IDEX's revenue in the third quarter 2026?
IDEX (IEX) reported revenue of $952M for the third quarter 2026 (Q3 2026), +8% from a year earlier and +3% from the quarter before.
Was IDEX profitable in the third quarter 2026?
Operating profit was $208M (21.9% of revenue) and net earnings $144M.
Source: IDEX 10-Q on SEC EDGAR.